ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.756,02
0,33%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,08499
0,02%
Bitcoin
68.765,28
0,37%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Virios Therapeutics Inc (VIRI)

  7. Virios Therapeutics Inc (VIRI) News

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VIRI
DatumZeitQuelleÜberschriftSymbolFirma
22/05/202419h30GlobeNewswire Inc.Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
20/05/202422h05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
20/05/202415h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
20/05/202402h53GlobeNewswire Inc.Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
17/05/202422h10GlobeNewswire Inc.Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
17/05/202422h01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
10/05/202416h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
09/05/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
09/05/202413h45GlobeNewswire Inc.Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
07/05/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
02/05/202415h15GlobeNewswire Inc.Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:VIRIVirios Therapeutics Inc
26/03/202414h15GlobeNewswire Inc.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
08/03/202423h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:VIRIVirios Therapeutics Inc
06/03/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
01/03/202415h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRIVirios Therapeutics Inc
29/02/202415h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
29/02/202415h15GlobeNewswire Inc.Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
28/02/202419h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202419h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202418h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202418h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202418h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202418h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202418h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202418h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202415h15GlobeNewswire Inc.Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesNASDAQ:VIRIVirios Therapeutics Inc
27/02/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
02/02/202422h31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202415h33Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202415h00GlobeNewswire Inc.Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRI

Kürzlich von Ihnen besucht

EU
D172S
D172S
EU
5794T
5794T
USOTC
BANGN
Versant Power (CE)
COIN
SET4ETH
Scarlett Exchange Token
USOTC
DRKOF
Martello Technologies (PK)
UNSW
TOMOEETH
TomoChain
USOTC
CNGKY
CK Asset (PK)
NYSE
HME
Home Properties
NASDAQ
NYMTO
New York Mortgage
ASX
LNGKOB
NASDAQ
BNGO
Bionano Genomics
NASDAQ
LSEAW
Landsea Homes
EU
EDI
Media 6
LSE
SMOT
Ve Smid Moat
ASX
BXBSWT
NASDAQ
AAZVDXX
Jpmorgan Chase Financial...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten